1. Control of Nitrosamine Impurities in Human Drugs, Center for Drug Evaluation and Research (CDER), U.S. Department of Health and Human Services Food and Drug Administration, 2021.
2. European medicines regulatory network approach for the implementation of the CHMP opinion pursuant to article 5(3) of Regulation (EC) 726/2004 for nitrosamine impurities in human medicines, 2021.
3. Prevalence of nitrosamine contaminants in drug samples: has the crisis been overcome?;Schmidtsdorff;Arch. Pharm.,2023
4. Development of a sensitive screening method for simultaneous determination of nine genotoxic nitrosamines in active pharmaceutical ingredients by GC-MS;Witkowska;Int. J. Mol. Sci.,2022
5. Recommended acceptable intake limits for nitrosamine drug substance-related impurities (NDSRIs), U.S. Department of Health and Human Services Food and Drug Administration, 2023.